AIDS Therapy

IND application filed for protease inhibitor GS 9005

Published in Drug Week, February 13th, 2004

Gilead Sciences, Inc., (GILD) has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to evaluate GS 9005 (formerly known as GS 4338) as a potential new therapy for HIV.

Under this IND, Gilead plans to assess the oral bioavailability, pharmacokinetics, safety, and efficacy of GS 9005 in healthy volunteers and HIV- positive patients. GS 9005 is a novel HIV protease inhibitor (PI) discovered at Gilead. Based on data from preclinical and in vitro studies, GS 9005 has the potential to be dosed as a single pill once daily and may have a clinical resistance profile that is distinct from commercially available drugs in the PI...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry